Maintenance Engineer

Job description:

Do you pride yourself on your integrity? We do what’s right for our employees, patients and partners so can you?

We are currently recruiting for an experienced Engineer to evaluate assets, determine and execute routine preventative maintenance activities and procedures and assess and implement major fault repairs.

Oxford Biomedica’s Engineering team are responsible for all aspects of Plant, Mechanical, Electrical, and incoming utilities at our facilities.

Your responsibilities in this role would be:

• Accountable for completion of assigned routine preventative maintenance activities.


• Respond to breakdowns of equipment, assessment, diagnosis, repair of faults or escalation.


• Co-ordination of OXB’s external engineering resource in relationship to specialist repairs and maintenance of assets.


• Completion of regulatory routine monitoring (Legionella tap temperatures for example)


• Evaluation of asset performance against determined criteria.


• Completion of quality documentation for critical failures.


• Identification of spares stock availability.


• Escalation of events impacting engineering assets.

Profile description:

To be successful in this role, you will have the following skills and experience:

• A minimum of 5 GCSE’s (or equivalent) including Maths and English


• An apprenticeship within a relevant discipline, NVQ 3 Level 3, City & Guilds or equivalent is preferred.


• Proven experience within an engineering maintenance function.


• Experience within a GxP Pharmaceutical/Biotech industry is preferred.


• Good computer Literacy skills with experience of Microsoft Office suite software.


• Experience in regulatory/statutory regulations.


• Good working knowledge of Health and Safety within an Engineering environment

About Us:

Oxford Biomedica is a quality and innovation-led viral vector CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, we have more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies.

Oxford Biomedica collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica’s world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods, and depth of regulatory expertise.

What’s in it for you:

• Highly competitive reward packages


• Wellbeing programmes


• Development opportunities


• A 35-hour working week.


• Welcoming, friendly, supportive colleagues


• A diverse and inclusive working environment


• Our values are: Deliver Innovation, Be Inspiring and Have Integrity


• State of the art laboratory and manufacturing facilities

We want you to feel inspired every day. We’re future-focused and our business is growing rapidly. We succeed together through passion, commitment, and teamwork, and so can you.

Collaborate. Contribute. Change lives

We offer:

Oxford Biomedica is a quality and innovation-led viral vector CDMO that enables its clients to deliver life-changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, Oxford Biomedica has more than 25 years of experience in viral vectors, the driving force behind the majority of gene therapies.

Cell and gene therapy is the treatment of disease by the delivery of therapeutic genetic material (DNA or RNA), into a patient’s cells. One highly effective approach to delivering genetic information is to re-engineer existing viruses to be safe delivery vehicles (vectors) to insert the genetic material into patients’ cells. This can be achieved either by directly administering the vector to the patient (often referred to as in vivo gene therapy), or by first introducing the genetic material to cells or tissue outside of the body, before administering the cells or tissue into the patient (often referred to as ex vivo gene therapy or gene-modified cell therapy).

Oxford Biomedica collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.